Parali, E. Et Al. 2014. THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY. VALUE IN HEALTH , vol.17, no.3 .

Parali, E., Deger, C., Ozdemir, O., AFSAR, N., Aykut Aka, S., Degertekin, M., ... Ergene, O.(2014). THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY. VALUE IN HEALTH , vol.17, no.3.

Parali, E. Et Al. "THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY," VALUE IN HEALTH , vol.17, no.3, 2014

Parali, E. Et Al. "THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY." VALUE IN HEALTH , vol.17, no.3, 2014

Parali, E. Et Al. (2014) . "THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY." VALUE IN HEALTH , vol.17, no.3.

@article{article, author={E. Parali Et Al. }, title={THE COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF CARDIOVASCULAR (CV) EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) IN TURKEY}, journal={VALUE IN HEALTH}, year=2014}